AstraZeneca
(NYSE:AZN) and Bristol-Myers
Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug
Administration (FDA) has approved Farxiga™ (dapagliflozin).
Please
click here for US Full Prescribing Information for Farxiga.
The companies will provide additional details regarding the approval in
a press release to follow.
About the AstraZeneca/Bristol-Myers Squibb Diabetes Alliance
Dedicated to addressing the global burden of diabetes by advancing
individualized patient care, AstraZeneca and Bristol-Myers Squibb are
working in collaboration to develop and commercialize a versatile
portfolio of innovative treatment options for diabetes and related
metabolic disorders that aim to provide treatment effects beyond glucose
control. Find out more about the Alliance and our commitment to meeting
the needs of health care professionals and people with diabetes at www.astrazeneca.com
or www.bms.com.
On December 19, 2013 AstraZeneca and Bristol-Myers Squibb announced an
agreement under which AstraZeneca will acquire the entirety of
Bristol-Myers Squibb’s interests in the companies’ diabetes alliance to
consolidate worldwide ownership of the diabetes business within
AstraZeneca. The closing of the transactions contemplated by the
agreement is subject to customary terms and conditions, and is expected
to occur during the first quarter of 2014.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of cardiovascular,
metabolic, respiratory, inflammation, autoimmune, oncology, infection
and neuroscience diseases. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
For more information please visit: www.astrazeneca.com.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
Media:Bristol-Myers SquibbKen Dominski, 609-252-5251ken.dominski@bms.comorAstraZenecaKristin Rogers, 302-885-8922kristin.rogers@astrazeneca.comorInvestors:Bristol-Myers SquibbRanya Dajani, 609-252-5330ranya.dajani@bms.comorRyan Asay, 609-252-5020ryan.asay@bms.comorAstraZenecaKarl Hard, 44-20-7604-8123karl.j.hard@astrazeneca.comorAnthony Brown, 44-20-7604-8067Anthony.brown@astrazeneca.comorJens Lindberg, 44-20-7604-8414jens.lindberg@astrazeneca.comorColleen Proctor, 302-886-1842colleen.proctor@astrazeneca.com